Teva Completes All-Israel CureTech Buy That Could Reach $1 Billion
This article was originally published in PharmAsia News
Executive Summary
Teva Pharmaceuticals Industries said it has completed its purchase of a major stake in fellow Israeli drug maker CureTech, a biotech developer of cancer treatments